Table 3.
Number of patients harboring NS3/4A PIs and NS5A protein inhibitors RAVs
| DAAs | RAVs | Number of patients (%) | Drugs |
|---|---|---|---|
| NS3/4A PIs | T54S | 8/145 (5.5) | Telaprevir, boceprevir, simeprevir, and faldaprevir |
| S122G | 82/145 (56.6) | Telaprevir, simeprevir | |
| V132I | 48/145 (33.1) | Only in vitro | |
| V170I | 19/145 (13.1) | Telaprevir | |
| NS5A protein inhibitors | R30Q | 9/148 (6.1) | Daclatasvir, ledipavir, and samatasvir |
| Q54H | 13/148 (8.8) | Daclatasvir, ABT267 | |
| P58S | 3/148 (2.0) | Daclatasvir | |
| Q62H | 5/148 (3.4) | Daclatasvir | |
| A92T | 3/148 (2.0) | Only in vivo | |
| Y93H | 14/148 (10.1) | Nearly all NS5A protein inhibitors |
DAAs: Direct-acting antivirals; RAVs: Resistance-associated variants; PI: Protease inhibitor.